Post-treatment outcomes of TP53-mutant Mantle Cell Lymphoma patients treated with frontline zanubrutinib, obinutuzumab, and venetoclax (BOVen): Durable responses in patients who achieve complete remissions with undetectable MRD
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Sean Healton, Jacob Soumerai, Jeffrey Barnes, Jason Brecher, Philip Caron, Shalini Chhabra, Maria Chabowska, Ahmet Dogan, Lorenzo Falchi, Clare Grieve, Erika Haydu, Patrick Connor Johnson, Ashlee Joseph, Alyssa Labarre, Jennifer Lue, Rosalba Martignetti, Joanna Mi, Alison Moskowitz, Colette Owens, Sean Plummer, Madeline Puccio, Venkatraman Seshan, Elizabeth Simkins, Natalie Slupe, Honglei Zhang, Gilles Salles, Andrew Zelenetz, Anita Kumar
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417019582